These benefits were paralleled by a -4.1 and -2.8 mmHg difference between the groups for systolic and diastolic blood pressure, respectively.
Patients randomized to nifedipine GITS but no RAS blockers (n=2966) when compared to those receiving RAS blockers but no nifedipine GITS (n=880) had highly statistically significant reductions in cardiovascular events (22%), newonset heart failure (53%), and debilitating stroke (45%). However, the groups differed in their baseline characteristics. Conclusion: Addition of nifedipine GITS to the treatment regimen of selected patient groups with symptomatic coronary artery disease results in a significant reduction of cardiovascular morbidity. While the interpretation of these subgroup analyses must obviously be cautious, there is a clear message relating to "best practice" treatment of angina, which suggests that "reliance" on RAS blockade may be misplaced and greater attention should be directed towards control of blood pressure. 
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The Thus, these present analyses have explored the outcome benefits attributable to the addition of nifedipine GITS in relation to the following different patterns of concurrent treatment:
Full "optimal" therapy at baseline (including 1. beta blockers, nitrates, aspirin, statins, and renin angiotensin system [RAS] blockers).
Full "optimal" therapy at baseline (as above) 2.
but excluding RAS-blocking drugs.
Treatment with nifedipine GITS in 3.
patients who were not treated with RAS blockers versus treatment with RAS blockers in patients who did not receive nifedipine GITS.
RESULTS
In brief, 7655 patients with angina pectoris were randomized to receive either nifedipine GITS (n=3825) or matching placebo (n=3840).
1) Outcome in Patients Receiving "Optimal"
Therapy at Baseline
Evaluation of the database of 7665 patients randomized in ACTION revealed that at baseline only 464 were receiving beta blockers, nitrates, aspirin, statins, and RAS blockers-this being defined as full optimal therapy as recommended by the current European guidelines.
1 Although the two groups (patients with angina pectoris receiving either nifedipine GITS or placebo)
were well matched for baseline characteristics, the small number of patients precluded any meaningful statistical analysis due to the lack of statistical power. Nonetheless, the summarized outcome findings are presented in Table 1 . Those patients randomized to nifedipine GITS attained lower blood pressure (BP) by the end of the trial (visit 18) than those randomized to placebo.
The mean difference between the groups was -5.1 and -2.7 mmHg for systolic and diastolic BP, respectively. All of the predefined outcomes favored nifedipine GITS with a 13% reduction in the primary outcome of efficacy, a 36% reduction in new-onset heart failure, and a 22% reduction in debilitating stroke (Table 1) . None of the reductions achieved statistical significance.
2) Outcome in Patients Receiving "Optimal" Therapy Excluding RAS Blockers at Baseline
A total of 2461 patients randomized in ACTION were receiving optimal therapy excluding RAS blockers at baseline. The demographic and clinical features of the 1223 patients randomized to nifedipine GITS and 1238 to placebo are detailed in Table 2 along with the drug therapy at baseline. It is apparent from Table 2 that although these patients are a selected group from the randomized population they are well matched for the baseline characteristics with no statistically significant differences between the two groups. Four years after randomization (visit 18), the achieved BP in the nifedipine GITS and placebo group were 129.9/75.2 and 134.4/78.0 mmHg, respectively. This represents a -4.1 and -2.8 mmHg difference in between the groups for SBP and DBP, respectively. Figure 1 shows the effects of nifedipine GITS (relative to placebo) on predefined ACTION combined endpoints in patients receiving optimal therapy excluding RAS blockers at baseline. As evidenced by 95% confidence intervals that do not include "no effect" (hazard ratio=1), nifedipine significantly reduced debilitating stroke by 48% (P<0.02) and the coronary angiography by 14% (P<0.05). There also were reductions associated with nifedipine GITS in all the other prespecified endpoints, but these did not achieve statistical significance (Figure 1 ).
3) Outcome in Patients Receiving Nifedipine
GITS but no RAS Blockers, Compared to Those Receiving RAS Blockers but No Nifedipine GITS
At total of 2966 patients in ACTION were randomized to nifedipine GITS but were not treated with RAS blockers, whilst 880 patients ACE=angiotensin-converting enzyme; MI=myocardial infarction; RAS=renin angiotensin system; SBP/DBP=systolic/diastolic blood pressure.
were treated with RAS blockers but did not receive nifedipine GITS (placebo). The demographic and clinical features of these patients are detailed in Table 3 along with the drug therapy at baseline.
It is apparent from Table 3 
DISCUSSION
Overall, the findings of these further analyses of the ACTION database suggest that there is considerable scope for improvement in the drug treatment of patients with stable coronary artery disease. The original aim of the ACTION trial was to establish the safety and efficacy of nifedipine GITS when added to "best practice treatment" of angina pectoris, 5,7 but it is now apparent that "best practice" or "optimal" treatment reflected an algorithm for drug therapy derived from disparate levels of evidence with, in many ACE=angiotensin-converting enzyme; GITS=gastrointestinal therapeutic system; MI=myocardial infarction; RAS=renin angiotensin system; SBP/DBP=systolic/diastolic blood pressure.
instances, of proof of efficacy being based upon reducing symptoms rather than improving outcome. 1 However, despite the relatively longestablished consensus on "optimal" treatment, only 6% of patients randomized in ACTION were receiving the full combination of beta blockers, nitrates, aspirin, statins, and drugs that block the RAS. 7 Nevertheless, it might have been anticipated that the outcome benefits seen in ACTION following the addition of nifedipine GITS 5,6 would predominantly have occurred in those patients receiving less than "optimal" therapy. In fact, the lowest rates for cardiovascular events were seen when treatment with nifedipine GITS was additional to "optimal" therapy (although the numbers in this retrospective analysis are too small for this to be considered definitive result). In addition to reducing cardiovascular morbidity, nifedipine treatment was associated with an expected further reduction in BP but it also should be borne in mind that nifedipine would likely also have provided additional symptomatic, antianginal benefit in such patients.
In those patients whose "optimal" therapy did not contain a RAS-blocking drug at baseline, the assessment of cardiovascular outcomes again suggested that nifedipine GITS offered specific benefits: particularly a 48% reduction in debilitating stroke and a 14% reduction in coronary angiography. Although these groups
were not independently randomized, they were found to be well matched at baseline with no statistical differences in their demographic features. The outcome benefits were paralleled by a greater BP reduction in the nifedipine GITS group, but nonetheless the selective benefit by way of stroke reduction is comparable with that achieved by ramipril in the HOPE trial. 
